Denmark· DK-28106082018
Ethosuximid "2care4"
A ethosuximide product containing ethosuximid, registered in Denmark by 2care4 ApS. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Ethosuximide is registered in 16 of 19 countries.
Countries holding a registration under ATC N03AD01 (ethosuximide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Ethosuximide · ATC N03AD01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ethosuximide costs, country by country.
Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ethosuximide · price per daily dose (1.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.83
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- ETHOSUXIMID
- Manufacturer
- 2care4 ApS
- Country
- Denmark (DK)
- ATC code
- N03AD01
- ATC class
- Ethosuximide
- Defined daily dose
- 1.25 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106082018
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
124 interactions on record for ethosuximide.
Graded by severity as the source publishes them — 124 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ethosuximide · interactions on record
124 records
- 124 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N03AD01
Ethosuximide, as other registers publish it.
- United KingdomEmeside 250mg capsulesFontus Health Ltd
- United KingdomEmeside 250mg/5ml syrupFontus Health Ltd
- United KingdomEpesri 250mg capsulesStrides Pharma UK Ltd
- United KingdomEpesri 250mg/5ml syrupStrides Pharma UK Ltd
- DenmarkEthonorNordic Prime ApS
- DenmarkEthosuximid "Ebb Medical"Ebb Medical AB
- GermanyEthosuximid GlenmarkGlenmark Arzneimittel Gmbh
- DenmarkEthosuximid MedartuumMedartuum AB
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/72f62379-a042-48f8-ad6c-6a7eff2ed008 GET /v1/drugs/72f62379-a042-48f8-ad6c-6a7eff2ed008?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "oral opløsning",
"source": "dkma",
"strength": "50 mg/ml",
"auth_role": "DKMA",
"dk_drugid": "28106082018",
"substance": "ETHOSUXIMID",
"auth_procedure": "Par-Imp",
"in_medicinpriser": true,
"registration_date_serial": "43234"
}See everything about ethosuximide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.